Registration Dossier

Administrative data

Key value for chemical safety assessment

Additional information

Valeryl chloride was tested in the Ames reverse mutation assay (GLP compliant OECD guideline 471/472 study) using Salmonella typhimurium strains TA98, TA100, TA1535 and TA1537 and Escherichia coli WP2 uvr A at 20 to 5000 µg/plate (standard plate test) and 20 to 1500 µg/plate (preincubation test) with and without metabolic activation (BASF AG, 1997). No precipitation of the test substance was found. A bacteriotoxic effect was observed at doses from 1,500 µg/plate (standard plate test) or from 500 µg/plate (preincubation test). Under the conditions tested, an increase in the number of his+ or trp+ revertants was not observed both in the standard plate test and in the preincubation test either without S-9 mix or after the addition of a metabolising system.


Short description of key information:
No data is available for isovaleryl chloride. However, the toxicological profile of the non-branched isomer valeryl chloride and isovaleryl chloride are very similar. Due to their reactivity both acid chlorides react locally with human tissue at the port of entry and/or hydrolyze to form hydrochloric acid and valeric acid or isovaleric acid. There is an Ames test available for valeryl chloride which can be used for the assessment of isovaleryl chloride.

Valeryl chloride did not cause gene mutations in Salmonella typhimurium and Escherichia coli (Ames test).

Endpoint Conclusion: No adverse effect observed (negative)

Justification for classification or non-classification

Based on the results of the Ames test, valeryl chloride does not need to be classified according to Directive 67/548/EEC and according to the EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.